Table 3

Confirmation of the top 18 T2DM-associated MVPs in LOLIPOP and FHS

CpG identifierChrGeneDiscovery, incident T2DMLOLIPOP, incident T2DMFHS, prevalent T2DM*
OR95% CIOR95% CIPβSEP
cg196930311TXNIP0.520.46–0.60.680.62–0.751.2E-14−2.6E-022.7E-031.6E-21
cg0650016121ABCG11.651.45–1.891.441.31–1.582.6E-141.5E-021.8E-037.1E-17
cg144761011PHGDH0.670.59–0.760.810.75–0.893.0E-06−1.6E-023.6E-031.5E-05
cg1402017617SLC9A3R11.631.4–1.91.141–1.294.3E-025.4E-031.5E-033.9E-04
cg1102468217SREBF11.561.35–1.791.401.26–1.572.2E-098.6E-031.6E-035.4E-08
cg0639716122SYNGR11.511.32–1.731.171.06–1.281.1E-039.6E-032.2E-031.6E-05
cg0057495811CPT1A0.690.61–0.780.800.74–0.881.1E-06−6.7E-037.9E-044.8E-17
cg0623542911NDUFV11.491.3–1.71.111–1.245.8E-022.4E-031.3E-036.5E-02
cg0577842417AKAP11.691.42–2.021.441.21–1.713.5E-054.9E-031.6E-032.5E-03
cg1137614711SLC43A10.680.59–0.770.850.74–0.971.5E-02−3.2E-031.2E-038.4E-03
cg048163117C7orf501.511.31–1.751.131–1.274.4E-022.0E-023.2E-038.4E-10
cg0271160819SLC1A50.690.6–0.790.840.76–0.939.7E-04−7.9E-031.7E-032.0E-06
cg08309687210.680.6–0.780.820.74–0.911.9E-04−7.8E-033.0E-031.0E-02
cg1351404271.421.25–1.611.040.94–1.154.4E-011.8E-041.4E-039.0E-01
cg0899406010PFKFB30.650.55–0.760.810.72–0.926.6E-04−1.6E-022.5E-038.5E-10
cg016767957POR1.561.33–1.841.090.95–1.262.2E-019.2E-032.4E-031.2E-04
cg251303811SLC9A11.491.29–1.731.231.09–1.391.2E-036.5E-031.7E-031.7E-04
cg1118322715MAN2A21.491.29–1.721.080.97–1.21.9E-014.6E-032.0E-032.2E-02
  • MVPs and individual cells with confirmed association P < 0.05 appear in boldface type. FHS: 403 case and 2,204 control subjects). LOLIPOP: 1,074 case and 1,590 control subjects. OR: odds ratio for T2DM per 1 SD in methylation intensity. Chr, chromosome.

  • * In FHS, β indicates difference in percentage DNAm intensity between case and control subjects, with adjustment for age, sex, principal components 1–3 (calculated from methylation data), batch, and family structure.